JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Co-Diagnostics Inc

Open

BrancheGesundheitswesen

0.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.21

Max

0.25

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.5M

-7.5M

Verkäufe

-99K

50K

Gewinnspanne

-14,983.533

Angestellte

132

EBITDA

4.3M

-7.2M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+300% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

14. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.1M

9.4M

Vorheriger Eröffnungskurs

0.25

Vorheriger Schlusskurs

0.25

Nachrichtenstimmung

By Acuity

50%

50%

175 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Co-Diagnostics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 21:42 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. Aug. 2025, 21:21 UTC

Ergebnisse
Wichtige Markttreiber

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. Aug. 2025, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. Aug. 2025, 19:15 UTC

Wichtige Markttreiber

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. Aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. Aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. Aug. 2025, 21:30 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 21:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. Aug. 2025, 21:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss $938M >RIG

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss/Shr $1.06 >RIG

4. Aug. 2025, 20:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. Aug. 2025, 20:15 UTC

Ergebnisse

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. Aug. 2025, 20:13 UTC

Ergebnisse

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. Aug. 2025, 20:09 UTC

Ergebnisse

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. Aug. 2025, 20:06 UTC

Ergebnisse

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. Aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. Aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. Aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. Aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer-Vergleich

Kursveränderung

Co-Diagnostics Inc Prognose

Kursziel

By TipRanks

300% Vorteil

12-Monats-Prognose

Durchschnitt 1 USD  300%

Hoch 1 USD

Tief 1 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Co-Diagnostics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

0.3495 / 0.3699Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

175 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.